Glucose metabolism and NRF2 coordinate the antioxidant response in melanoma resistant to MAPK inhibitors

Targeted therapies as BRAF and MEK inhibitor combination have been approved as first-line treatment for BRAF-mutant melanoma. However, disease progression occurs in most of the patients within few months of therapy. Metabolic adaptations have been described in the context of acquired resistance to B...

Descripción completa

Detalles Bibliográficos
Autores principales: Khamari, Raeeka, Trinh, Anne, Gabert, Pierre Elliott, Corazao-Rozas, Paola, Riveros-Cruz, Samuel, Balayssac, Stephane, Malet-Martino, Myriam, Dekiouk, Salim, Joncquel Chevalier Curt, Marie, Maboudou, Patrice, Garçon, Guillaume, Ravasi, Laura, Guerreschi, Pierre, Mortier, Laurent, Quesnel, Bruno, Marchetti, Philippe, Kluza, Jerome
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5832419/
https://www.ncbi.nlm.nih.gov/pubmed/29487283
http://dx.doi.org/10.1038/s41419-018-0340-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5832419/
https://www.ncbi.nlm.nih.gov/pubmed/29487283
http://dx.doi.org/10.1038/s41419-018-0340-4

Ejemplares similares